Efficacy of adjuvant XELOX and FOLFOX6 chemotherapyafter D2 dissection for gastric cancer

World Journal of Gastroenterology

Volumn 19, Issue 21, 2013, Pages 3309-3315

  Wu, Ying ^a   Wei, Zhe Wei ^a   He, Yu Long ^a   Schwarz, Roderich E ^b   Smith, David D ^c   Xia, Guang Kai ^a   Zhang, Chang Hua ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b Indiana University   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

5 fluorouracil; Adjuvant; Capecitabine and oxaliplatin; D2 dissection; Folinic acid and oxaliplatin; Gastric cancer

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; ANOREXIA; ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; ORAL MUCOSITIS; OVERALL SURVIVAL; RECURRENCE RISK; RETROSPECTIVE STUDY; SIDE EFFECT; STOMACH CANCER; SURVIVAL RATE; THROMBOCYTOPENIA; TUMOR DIFFERENTIATION; VOMITING;

EID: 84878591707     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i21.3309     Document Type: Article

References (33)

1. Sasako M, Inoue M, Lin JT, Khor C, Yang HK, Ohtsu A. Gastric Cancer Working Group report. Jpn J Clin Oncol 2010; 40 Suppl 1: i28-i37.[PMID: 20870917 DOI: 10.1093/jjco/ hyq124]
2. Sasako M, Saka M, Fukagawa T, Katai H, Sano T. Modern surgery for gastric cancer--Japanese perspective. Scand J Surg 2006; 95: 232-235.[PMID: 17249270]
3. Kodera Y, Schwarz RE, Nakao A. Extended lymph node dissection in gastric carcinoma: where do we stand after the Dutch and British randomized trials? J Am Coll Surg 2002; 195: 855-864.[PMID: 12495318]
4. A, Bray F, Center M.M, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.[DOI: 10.3322/caac.20107]
5. Schwarz RE, Zagala-Nevarez K. Recurrence patterns after radical gastrectomy for gastric cancer: prognostic factors and implications for postoperative adjuvant therapy. Ann Surg Oncol 2002; 9: 394-400.[PMID: 11986192]
6. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF, Lui WY, Whang-Peng J. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 2006; 7: 309-315.[PMID: 16574546]
7. Zhang CH, Zhan WH, He YL, Chen CQ, Huang MJ, Cai SR. Spleen preservation in radical surgery for gastric cardia cancer. Ann Surg Oncol 2007; 14: 1312-1319. [PMID: 17265118]
8. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow- up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010; 11: 439-449.[PMID: 20409751 DOI: 10.1016/S1470-2045(10)70070-X]
9. Degiuli M, Sasako M, Calgaro M, Garino M, Rebecchi F, Mineccia M, Scaglione D, Andreone D, Ponti A, Calvo F. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. Eur J Surg Oncol 2004; 30: 303-308.[PMID: 15028313]
10. Okines A, Verheij M, Allum W, Cunningham D, Cervantes A. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 Suppl 5: v50-v54.[PMID: 20555102 DOI: 10.1093/annonc/mdq164]
11. Maehara Y, Hasuda S, Koga T, Tokunaga E, Kakeji Y, Sugimachi K. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg 2000; 87: 353-357. [PMID: 10718807]
12. Xu J, Zhang C, He Y, Wu H, Wang Z, Song W, Li W, He W, Cai S, Zhan W. Lymphatic endothelial cell-secreted CXCL1 stimulates lymphangiogenesis and metastasis of gastric cancer. Int J Cancer 2012; 130: 787-797.[PMID: 21387301 DOI: 10.1002/ijc.26035]
13. Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Van Cutsem E, Buyse M. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010; 303: 1729-1737.[PMID: 20442389 DOI: 10.1001/jama.2010.534]
14. Cunningham D, Okines AF, Ashley S. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2010; 362: 858-859.[PMID: 20200397 DOI: 10.1056/ NEJMc0911925]
15. Zhang C, Awasthi N, Schwarz MA, Schwarz RE. Establishing a peritoneal dissemination xenograft mouse model for survival outcome assessment of experimental gastric cancer. J Surg Res 2013; 182: 227-234.[PMID: 23201270 DOI: 10.1016/ j.jss.2012.10.052]
16. Oyama K, Fushida S, Kinoshita J, Makino I, Nakamura K, Hayashi H, Nakagawara H, Tajima H, Fujita H, Takamura H, Ninomiya I, Kitagawa H, Tani T, Fujimura T, Ohta T. Efficacy of pre-operative chemotherapy with docetaxel, cisplatin, and S-1 (DCS therapy) and curative resection for gastric cancer with pathologically positive para-aortic lymph nodes. J Surg Oncol 2012; 105: 535-541.[PMID: 22006649 DOI: 10.1002/jso.22125]
17. Osti MF, Agolli L, Bracci S, Monaco F, Tubin S, Minniti G, De Sanctis V, Enrici RM. Adjuvant chemoradiation with 5-fluorouracil or capecitabine in patients with gastric cancer after D2 nodal dissection. Anticancer Res 2012; 32: 1397-1402.[PMID: 22493376]
18. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-1820.[PMID: 17978289]
19. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9: 215-221.[PMID: 18282805 DOI: 10.1016/S1470-2045(08)70035-4]
20. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.[PMID: 11547741]
21. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20. [PMID: 16822992]
22. Ku GY, Ilson DH. Adjuvant therapy in esophagogastric adenocarcinoma: controversies and consensus. Gastrointest Cancer Res 2012; 5: 85-92.[PMID: 22888388]
23. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, Noh SH. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012; 379: 315-321.[PMID: 22226517 DOI: 10.1016/ S0140-6736(11)61873-4]
24. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471-1474.[PMID: 20180029 DOI: 10.1245/s10434-010-0985-4]
25. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-2281.[PMID: 9802183]
26. Newgard CD, Hedges JR, Arthur M, Mullins RJ. Advanced statistics: the propensity score--a method for estimating treatment effect in observational research. Acad Emerg Med 2004; 11: 953-961. [PMID: 15347546]
27. Schwarz RE, Smith DD, Keny H, Iklé DN, Shibata SI, Chu DZ, Pezner RD. Impact of intraoperative radiation on postoperative and disease-specific outcome after pancreatoduodenectomy for adenocarcinoma: a propensity score analysis. Am J Clin Oncol 2003; 26: 16-21.[PMID: 12576918]
28. Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y, Sasako M, Kunii Y, Motohashi H, Yamamoto S. Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol 2003; 21: 2282-2287.[PMID: 12805327]
29. Miyashiro I, Furukawa H, Sasako M, Yamamoto S, Nashimoto A, Nakajima T, Kinoshita T, Kobayashi O, Arai K. Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer versus curative resection alone: final results of the Japan Clinical Oncology Group trial JCOG9206-2. Gastric Cancer 2011; 14: 212-218.[PMID: 21336855 DOI: 10.1007/s10120-011-0027-3]
30. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, Price T, Anderson H, Iveson T, Hickish T, Lofts F, Norman A. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002; 20: 1996-2004.[PMID: 11956258]
31. Wacheck V, Heere-Ress E, Halaschek-Wiener J, Lucas T, Meyer H, Eichler HG, Jansen B. Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model. J Mol Med (Berl) 2001; 79: 587-593.[PMID: 11692156]
32. Chen S, Feng X, Li Y, Yuan X, Zhou Z, Chen Y. Efficacy and safety of XELOX and FOLFOX6 adjuvant chemotherapy following radical total gastrectomy. Oncol Lett 2012; 3: 781-786.[PMID: 22740993]
33. Cassidy J, Saltz L, Twelves C, Van Cutsem E, Hoff P, Kang Y, Saini JP, Gilberg F, Cunningham D. Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta- analysis of individual data from 6171 patients. Ann Oncol 2011; 22: 2604-2609.[PMID: 21415237 DOI: 10.1093/annonc/ mdr031]